These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 28854832)

  • 21. Clinical pharmacokinetics and pharmacodynamics of dolutegravir used as a single tablet regimen for the treatment of HIV-1 infection.
    Bollen P; Reiss P; Schapiro J; Burger D
    Expert Opin Drug Saf; 2015; 14(9):1457-72. PubMed ID: 26134478
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Two-drug regimens for treatment of naïve HIV-1 infection and as maintenance therapy.
    Corado KC; Caplan MR; Daar ES
    Drug Des Devel Ther; 2018; 12():3731-3740. PubMed ID: 30464404
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and Efficacy of Dolutegravir Plus Rilpivirine in Treatment-Experienced HIV-Infected Patients: The DORIVIR Study.
    Palacios R; Mayorga M; González-Domenech CM; Hidalgo-Tenorio C; Gálvez C; Muñoz-Medina L; de la Torre J; Lozano A; Castaño M; Omar M; Santos J
    J Int Assoc Provid AIDS Care; 2018; 17():2325958218760847. PubMed ID: 29529910
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Switch to Dolutegravir plus Rilpivirine Dual Therapy in cART-Experienced Subjects: An Observational Cohort.
    Capetti AF; Sterrantino G; Cossu MV; Orofino G; Barbarini G; De Socio GV; Di Giambenedetto S; Di Biagio A; Celesia BM; Argenteri B; Rizzardini G
    PLoS One; 2016; 11(10):e0164753. PubMed ID: 27741309
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Juluca - a two-drug complete regimen for HIV.
    Med Lett Drugs Ther; 2018 Dec; 60(1561):e202-e204. PubMed ID: 30653480
    [No Abstract]   [Full Text] [Related]  

  • 26. Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect?
    Cattaneo D; Minisci D; Cozzi V; Riva A; Meraviglia P; Clementi E; Galli M; Gervasoni C
    Antivir Ther; 2017; 22(4):353-356. PubMed ID: 28008867
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dolutegravir plus rilpivirine as dual regimen in virologically suppressed HIV-1 infected patients in a clinical setting.
    Casado JL; Monsalvo M; Fontecha M; Vizcarra P; Rodriguez MA; Vivancos MJ; Moreno S
    HIV Res Clin Pract; 2019 Apr; 20(2):64-72. PubMed ID: 31303142
    [No Abstract]   [Full Text] [Related]  

  • 28. Development and Validation of a Chromatographic Ultraviolet Method for the Simultaneous Quantification of Dolutegravir and Rilpivirine in Human Plasma.
    Cozzi V; Charbe N; Baldelli S; Castoldi S; Atzori C; Cattaneo D; Clementi E
    Ther Drug Monit; 2016 Jun; 38(3):407-13. PubMed ID: 26885814
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual antiretroviral therapy for HIV infection.
    Soriano V; Fernandez-Montero JV; Benitez-Gutierrez L; Mendoza C; Arias A; Barreiro P; Peña JM; Labarga P
    Expert Opin Drug Saf; 2017 Aug; 16(8):923-932. PubMed ID: 28621159
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risks and benefits of reducing the number of drugs to treat HIV-1 infection.
    Cadiñanos J; Montejano R; de Miguel Buckley R; Marcelo C; Arribas JR
    Expert Opin Drug Saf; 2021 Apr; 20(4):397-409. PubMed ID: 33557651
    [No Abstract]   [Full Text] [Related]  

  • 31. Enteral Administration of Twice-Daily Dolutegravir and Rilpivirine as a Part of a Triple-Therapy Regimen in a Critically Ill Patient with HIV.
    Turley SL; Fulco PP
    J Int Assoc Provid AIDS Care; 2017; 16(2):117-119. PubMed ID: 28198203
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysing the efficacy and tolerability of dolutegravir plus either rilpivirine or lamivudine in a multicentre cohort of virologically suppressed PLWHIV.
    Ciccullo A; Baldin G; Borghi V; Cossu MV; Giacomelli A; Lagi F; Farinacci D; Iannone V; Passerotto RA; Capetti A; Sterrantino G; Mussini C; Antinori S; Di Giambenedetto S
    J Antimicrob Chemother; 2022 Dec; 78(1):117-121. PubMed ID: 36272137
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dolutegravir/lamivudine (Dovato)--a two-drug complete regimen for HIV-1 infection.
    Med Lett Drugs Ther; 2019 Aug; 61(1579):134-136. PubMed ID: 31581158
    [No Abstract]   [Full Text] [Related]  

  • 34. Neurotoxicities in the treatment of HIV between dolutegravir, rilpivirine and dolutegravir/rilpivirine: a meta-analysis.
    Allen Reeves A; Fuentes AV; Caballero J; Thomas JE; Mosley Ii JF; Harrington C
    Sex Transm Infect; 2021 Jun; 97(4):261-267. PubMed ID: 33782144
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of dolutegravir/rilpivirine in real-world clinical practice. GeSIDA study 1119.
    Palacios R; Gómez-Ayerbe C; Casado JL; Tejerina F; Montes ML; Castaño M; Ocampo A; Rial D; Ribera E; Galindo MJ; Hidalgo C; Fariñas C; Montero M; Payeras T; Fanjul F; de la Torre J; Santos J
    HIV Med; 2023 Aug; 24(8):933-937. PubMed ID: 37016556
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dolutegravir Plus Rilpivirine as a Switch Option in cART-Experienced Patients: 96-Week Data.
    Capetti AF; Cossu MV; Sterrantino G; Barbarini G; Di Giambenedetto S; De Socio GV; Orofino G; Di Biagio A; Celesia BM; Rusconi S; Argenteri B; Rizzardini G
    Ann Pharmacother; 2018 Aug; 52(8):740-746. PubMed ID: 29482352
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Switch from unboosted protease inhibitor to a single-tablet regimen containing rilpivirine improves cholesterol and triglycerides.
    Di Biagio A; Riccardi N; Taramasso L; Capetti A; Cenderello G; Signori A; Vitiello P; Guerra M; de Socio GV; Cassola G; Quirino T; Viscoli C
    Int J Antimicrob Agents; 2016 Nov; 48(5):551-554. PubMed ID: 27566908
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study.
    Clotet B; Feinberg J; van Lunzen J; Khuong-Josses MA; Antinori A; Dumitru I; Pokrovskiy V; Fehr J; Ortiz R; Saag M; Harris J; Brennan C; Fujiwara T; Min S;
    Lancet; 2014 Jun; 383(9936):2222-31. PubMed ID: 24698485
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Brief Report: Evaluation of Inflammation and Atherogenesis Biomarkers Through 148 Weeks Postswitch to Dolutegravir and Rilpivirine in SWORD-1/SWORD-2.
    Llibre JM; López Cortés LF; Aylott A; Wynne B; Matthews J; Van Solingen-Ristea R; Vandermeulen K; van Wyk J; Kahl LP
    J Acquir Immune Defic Syndr; 2022 Sep; 91(1):73-78. PubMed ID: 35551149
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness and safety of an abacavir/lamivudine + rilpivirine regimen for the treatment of HIV-1 infection in naive patients.
    Curran A; Rojas J; Cabello A; Troya J; Imaz A; Domingo P; Martinez E; Ryan P; Górgolas M; Podzamczer D; Knobel H; Gutiérrez F; Ribera E
    J Antimicrob Chemother; 2016 Dec; 71(12):3510-3514. PubMed ID: 27591292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.